Vandetanib in Advanced Medullary Thyroid Cancer: Review of Adverse Event Management Strategies

INTRODUCTION: Vandetanib has recently demonstrated clinically meaningful benefits in patients with unresectable, locally advanced or metastatic medullary thyroid cancer (MTC). Given the potential for long-term vandetanib therapy in this setting, in addition to treatment for disease-related symptoms,...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Grande, Enrique, Kreissl, Michael C., Filetti, Sebastiano, Newbold, Kate, Reinisch, Walter, Robert, Caroline, Schlumberger, Martin, Tolstrup, Lærke K., Zamorano, Jose L., Capdevila, Jaume
Format: Artigo
Jezik:Inglês
Izdano: Springer Healthcare 2013
Teme:
Review
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3898148/
https://ncbi.nlm.nih.gov/pubmed/24249433
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-013-0069-5
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items